Study Of REGN4018 Administered Alone Or In Combination With Cemiplimab In Adult Patients With Recurrent Ovarian Cancer Or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Overview

About this study

Primary Objectives In the Dose Escalation Phase:

  • To assess the safety and pharmacokinetics (PK) in order to determine a maximally tolerated dose (MTD) or recommended phase 2 dose (RP2D) of REGN4018 as monotherapy and in combination with cemiplimab.

In the Dose Expansion Phase:

  • To assess the preliminary efficacy of REGN4018 as monotherapy and in combination with cemiplimab, (separately by cohort) as determined by the objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

Secondary Objectives In the Dose Escalation Phase:

  • To assess the preliminary efficacy of REGN4018 as monotherapy and in combination with cemiplimab (separately by cohort) as determined by ORR by RECIST 1.1.

In the Dose Expansion Phase:

  • To characterize the safety profile in each expansion cohort.
  • To characterize the PK of REGN4018 as monotherapy and in combination with cemiplimab.
  • To assess the effects of REGN4018 as monotherapy and in combination with cemiplimab on patient-reported outcomes (PROs), including health-related quality of life (HRQoL), functioning, and symptoms.

In both the Dose Escalation and Dose Expansion Phases:

  • To assess preliminary efficacy of REGN4018 as monotherapy and in combination with cemiplimab (separately by cohort) as measured by ORR based on iRECIST, best overall response (BOR), duration of response (DOR), disease control rate, complete response (CR) rate and progression-free survival (PFS) based on RECIST 1.1 and iRECIST.
  • To assess efficacy of REGN4018 as monotherapy and in combination with cemiplimab as measured by CA-125 level.
  • Immunogenicity of REGN4018 and cemiplimab.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Key Inclusion Criteria:

1. Patients with histologically or cytologically confirmed diagnosis of advanced,
epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian
tube cancer who have all of the following:

1. serum CA-125 level ≥2x upper limit of normal (ULN) (in screening)

2. has received at least 1 line of platinum-containing therapy or must be
platinum-intolerant (applicable for dose escalation and non-randomized dose
expansion cohorts)

3. documented relapse or progression on or after the most recent line of therapy

4. no standard therapy options

2. Adequate organ and bone marrow function as defined in the protocol

3. Life expectancy of at least 3 months

4. Randomized phase 2 expansion cohorts only: Platinum resistant ovarian cancer patients
who have only had 1 to 3 lines of platinum-based therapy prior treatment with poly
ADP-ribose polymerase (PARP) inhibitor or bevacizumab as defined in the protocol.

Key Exclusion Criteria:

1. Recent treatment with anti-Programmed Cell Death (PD-1)/PD-L1 therapy

2. Expansion cohort only: More than 4 prior lines of cytotoxic chemotherapy

3. Prior treatment with a Mucin 16 (MUC16)-targeted therapy

4. Untreated or active primary brain tumor, central nervous system (CNS) metastases, or
spinal cord compression

5. History and/or current cardiac findings as defined in the protocol

6. Severe and/or uncontrolled hypertension at screening. Patients taking
anti-hypertensive medication must be on a stable anti-hypertensive regimen

Note: Other protocol Inclusion/Exclusion Criteria apply

Eligibility last updated 8/3/22. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Block, M.D., Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions